Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan;23(3):17-00838.
doi: 10.2807/1560-7917.ES.2018.23.3.17-00838.

Distinction between serological responses following tick-borne encephalitis virus (TBEV) infection vs vaccination, Sweden 2017

Bo Albinsson  1   2 , Sirkka Vene  1   3 , Lars Rombo  4   5 , Jonas Blomberg  1   6 , Åke Lundkvist  1 , Bengt Rönnberg  1   2
Affiliations

Distinction between serological responses following tick-borne encephalitis virus (TBEV) infection vs vaccination, Sweden 2017

Bo Albinsson et al. Euro Surveill. 2018 Jan.

Abstract

Tick-borne encephalitis virus (TBEV) is an important European vaccine-preventable pathogen. Discrimination of vaccine-induced antibodies from those elicited by infection is important. We studied anti-TBEV IgM/IgG responses, including avidity and neutralisation, by multiplex serology in 50 TBEV patients and 50 TBEV vaccinees. Infection induced antibodies reactive to both whole virus (WV) and non-structural protein 1 (NS1) in 48 clinical cases, whereas 47 TBEV vaccinees had WV, but not NS1 antibodies, enabling efficient discrimination of infection/vaccination.

Keywords: Tick-borne encephalitis (TBE); diagnostics; vaccine-preventable diseases; vaccines and immunisation; viral encephalitis; zoonotic infections.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared.

Figures

Figure 1
Figure 1
Suspension multiplex immunoassay for IgM reactivity with tick-borne encephalitis whole virus vs non-structural protein 1 antigens in infected (n = 50) vs vaccinated individuals (n = 50) at 0, 120 and 390 days after first vaccination, Sweden, 2017
Figure 2
Figure 2
Suspension multiplex immunoassay for IgG reactivity with tick-borne encephalitis whole virus vs non-structural protein 1 antigens in infected (n = 50) vs vaccinated individuals (n = 50) at 0, 120 and 390 days after first vaccination, Sweden, 2017
Figure 3
Figure 3
Suspension multiplex immunoassay avidity index for IgG against tick-borne encephalitis whole virus in infected patients (n = 50) vs vaccinees (n = 50), and neutralisation titres at 0, 120 and 390 days after the first vaccination, Sweden, 2017
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rönnberg B, Gustafsson Å, Vapalahti O, Emmerich P, Lundkvist Å, Schmidt-Chanasit J, et al. Compensating for cross-reactions using avidity and computation in a suspension multiplex immunoassay for serotyping of Zika versus other flavivirus infections. Med Microbiol Immunol (Berl). 2017;206(5):383-401. 10.1007/s00430-017-0517-y - DOI - PMC - PubMed
    1. Vene S, Haglund M, Vapalahti O, Lundkvist A. A rapid fluorescent focus inhibition test for detection of neutralizing antibodies to tick-borne encephalitis virus. J Virol Methods. 1998;73(1):71-5. 10.1016/S0166-0934(98)00041-X - DOI - PubMed
    1. Hertzell KB, Pauksens K, Rombo L, Knight A, Vene S, Askling HH. Tick-borne encephalitis (TBE) vaccine to medically immunosuppressed patients with rheumatoid arthritis: A prospective, open-label, multi-centre study. Vaccine. 2016;34(5):650-5. 10.1016/j.vaccine.2015.12.029 - DOI - PubMed
    1. Lindquist L, Vapalahti O. Tick-borne encephalitis. Lancet. 2008;371(9627):1861-71. 10.1016/S0140-6736(08)60800-4 - DOI - PubMed
    1. Dobler G, Tkachev S. General epidemiology of tick-borne encephalitis. In: Dobler G, Erber W, Schmitt HJ. TBE-The Book. Singapore: Global Health Press; 2017. ISBN: 978-981-1903-3. Available from: https://id-ea.org/tbe

MeSH terms